Key features of invasive pneumococcal isolates recovered in Lima, Peru determined through whole genome sequencing

Paulina Hawkins1, Erik Mercado2, Sopio Chochua3

  • 1Emory University, Atlanta, USA; Centers for Disease Control and Prevention, Atlanta, USA.

Insights

Pneumococcal conjugate vaccine 7 (PCV7) introduction in Peru altered invasive pneumococcal disease (IPD) serotype distribution and reduced PCV7 serotype prevalence. Antimicrobial resistance remained high, with emerging non-vaccine serotypes showing resistance.

Area of Science:

  • Microbiology
  • Genomics
  • Epidemiology

Background:

  • Invasive pneumococcal disease (IPD) caused significant child mortality in Latin America before vaccine introduction.
  • Peru introduced the 7-valent pneumococcal conjugate vaccine (PCV7) in 2009 to combat IPD.
  • Understanding the impact of PCV7 on circulating strains and antimicrobial resistance is crucial for public health.

Purpose of the Study:

  • To analyze the genomic features of invasive pneumococcal isolates in Lima, Peru, before and after PCV7 introduction.
  • To identify changes in serotype prevalence, sequence types (STs), and antimicrobial resistance patterns post-PCV7 implementation.

Main Methods:

  • Whole genome sequencing of 212 IPD isolates collected from 2006 to 2011 in Lima, Peru.
  • Bioinformatic analysis using CDC's Streptococcus pipeline to determine serotypes, STs, pilus genes, and resistance determinants.
  • Comparison of isolate characteristics between the pre-PCV7 (2006-2009) and post-PCV7 (2010-2011) periods.

Main Results:

  • A significant decrease in PCV7 serotype 6B was observed post-introduction (24.8% to 6.3%).
  • Non-vaccine serotypes 19F and 19A showed increased prevalence post-PCV7.
  • High rates of antimicrobial resistance determinants were found in 82% of isolates, with 34% carrying resistance to multiple drug classes.

Conclusions:

  • PCV7 introduction effectively reduced the prevalence of vaccine-targeted serotypes in Peru.
  • Emerging non-vaccine serotypes, particularly 19F and 19A, are becoming dominant and carry significant antimicrobial resistance.
  • Continued genomic surveillance is essential to monitor IPD trends and inform vaccination and treatment strategies.